Ultragenyx Pharmaceutical Inc (RARE) - News Archive

Ultragenyx Pharmaceutical Inc. recently released compelling data from the Phase 2/3 Orbit study, highlighting the sustained reductions in fracture rates observed in patients with osteogenesis imperfecta (OI) following t...

Advancements in medical research and technology continue to revolutionize treatment options for rare genetic disorders. Recent breakthroughs in gene therapy have demonstrated promising results in addressing the complex...

NOVATO, Calif., May 17, 2024 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced today the grant of 17,180 restricted stock units of the company s common stock to ten newly hired non-executive officers. The awards...

In a significant leap forward in the clinical trial world, Ultragenyx Pharmaceutical Inc., a leading biopharmaceutical company in the field of rare and ultra-rare genetic diseases, announced the completion of patient en...

Ultragenyx, a biopharmaceutical company focused on the development of innovative therapies, has recently announced positive interim results from its Phase 1/2 clinical trial evaluating GTX-102 for the treatment of Angel...

Ultragenyx Awards Restricted Stock Units to New Non-Executive Officers: A Strong Signal of Growth and Attractiveness to Top TalentNOVATO, Calif., Feb. 23, 2024 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharm...

:Sanfilippo Syndrome Type A, also known as Mucopolysaccharidosis type IIIA (MPS IIIA), is a rare genetic disorder characterized by the accumulation of heparan sulfate within the body, leading to severe neurological impa...

Wilson Disease (WD) is a rare, genetic disorder characterized by the body s inability to properly metabolize copper, leading to its accumulation in vital organs such as the liver, brain, and other tissues. Current treat...

NOVATO, Calif., Jan. 19, 2024 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a leading biopharmaceutical company specializing in the development and commercialization of groundbreaking therapies for rare and ultrarare...

Ultragenyx s Evkeeza Receives Positive Recommendation for Homozygous Familial Hypercholesterolemia Treatment in the UKJanuary 4, 2024Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has recently announced that the National...

:Ultragenyx Pharmaceutical Inc. recently announced the completion of enrollment in its global Phase 1/2 trial of GTX-102 for the treatment of Angelman Syndrome in pediatric patients. This crucial development elucidates...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Dec. 21, 2023 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a leading biopharmaceutical company specializing in the development...

Ultragenyx Pharmaceutical Inc. Grants Restricted Stock Units to New Hires Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Oct. 20, 2023 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company de...